AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (4.7 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Green Synthesis of Selenium Nanoparticles in the Presence of Mycobacterium Bovis Cell Lysate: a Novel Fabrication Approachand its Immune-Modulatory Effects

Mohammad Hossein Yazdi1,2( )Seyed Mehdi Hassanzade3Ramak Ajideh4Maryam Mozafar4Faranak Mavandadnejad4Sara Rahimzadeh4Mehdi Mahdavi2Ahmad Reza Shahverdi4( )
Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
BCG Vaccine Department, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Show Author Information

Abstract

Mycobacterium bovis (M. bovis) is a slow-growing bacteria that can intracellularly reduce selenium ions to elemental selenium nanoparticles (SeNPs). We used bacterial lysates along with vitamin C to help the synthesis of SeNPs coated with M. bovis Bacille Calmette-Guérin (BCG) crude hydrophobic materials. However, the large-scale fabrication, separation, extraction, and purification of intercellular SeNPs which are prepared by using M. bovis, have many complexities. So, we developed a simple method for preparation of above BCG-coated nanoparticles and tested its potential immune-modulatory effects. In the current investigation, we cultivated the M. bovis in conventional media and prepared total cell lysates from this bacterium by just applying freeze and thaw and ultra-sonication. The resulting cell lysates were added to the solution containing selenium ions before adding the ascorbic acid as a reducing agent. At the end of the process, the fabricated selenium nanoparticles were separated by centrifugation and characterized by different instrumentation methods. In the next step, to evaluate the immune-modulatory effects of the hepatitis B surface antigen (HBsAg) vaccine alone, and in combination with plain SeNPs or SeNPs-BCG lysate, the serum level of interferon-gamma (IFN-γ) was determined in different groups by enzyme-linked immunosorbent assay (ELISA). This study showed adjuvant effects of prepared nanoparticles (in both 10 μg/300 μL and 100 μg/300 μL doses) in increasing the level of interferon-gamma (IFN-γ) in comparison with vaccine alone. Moreover, in both doses of SeNPs-BCG lysate, the level of interferon-gamma (IFN-γ) was remarkably higher than the same doses of plain SeNPs. As a result, synthesized SeNPs in the presence of whole-cell lysates of M. bovis indicated a greater ability to induce the interferon-gamma (IFN-γ) compared with other groups. Additionally, its easy fabrication procedure can be considered its superiority.

References

[1]

S. Hasan. A review on nanoparticles: Their synthesis and types. Research Journal of Recent Sciences, 2015, 4(SC-2014): 1‒3. http://www.isca.in/rjrs/archive/special-ISC-2014/3.ISCA-ISC-2014-Poster-3BS-63.pdf

[2]

S. Anu Mary Ealia, M.P. Saravanakumar. A review on the classification, characterisation, synthesis of nanoparticles and their application. IOP Conference Series: Materials Science and Engineering, 2017, 263(3): 032019. https://doi.org/10.1088/1757-899x/263/3/032019

[3]

S. Shirsat, A. Kadam, M. Naushad, et al. Selenium nanostructures: Microbial synthesis and applications. RSC Advances, 2015, 5: 92799‒92811. http://dx.doi.org/10.1039/C5RA17921A

[4]

S. Dwivedi, A.A. Alkhedhairy, M. Ahamed, et al. Biomimetic synthesis of selenium nanospheres by bacterial strain JS-11 and its role as a biosensor for nanotoxicity assessment: A novel se-bioassay. PLoS One, 2013, 8(3): e57404. https://doi.org/10.1371/journal.pone.0057404

[5]

B. Hosnedlova, M. Kepinska, S. Skalickova, et al. Nano-selenium and its nanomedicine applications: A critical review. International Journal of Nanomedicine, 2018, 13: 2107‒2128. https://doi.org/10.2147/ijn.s157541

[6]

M.H. Yazdi, M. Mahdavi, B. Varastehmoradi, et al. The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: An in vivo study. Biological Trace Element Research, 2012, 149: 22‒28. http://dx.doi.org/10.1007/s12011-012-9402-0

[7]

M. Mahdavi, F. Mavandadnejad, M.H. Yazdi, et al. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model. Journal of Infection and Public Health, 2017, 10: 102‒109. http://dx.doi.org/10.1016/j.jiph.2016.02.006

[8]

N. Posuwan, N. Wanlapakorn, P. Sa-Nguanmoo, et al. The success of a universal hepatitis B immunization program as part of Thailand's EPI after 22 years' implementation. PLoS One, 2016, 11(3): e0150499. https://doi.org/10.1371/journal.pone.0150499

[9]

M. Mendy, I. Peterson, S. Hossin, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian Villages: No need for a booster dose. PLoS One, 2013, 8(3): e58029. https://doi.org/10.1371/journal.pone.0058029

[10]

S.M. Alavian. Networking for overcoming on viral hepatitis in middle east and central Asia: Asian hepatitis network. Hepatitis Monthly, 2007, 7(4): 181‒182. https://www.sid.ir/paper/306148/en

[11]

D. Bhattacharya, C.L. Thio. Review of hepatitis B therapeutics. Clinical Infectious Diseases, 2010, 51(10): 1201‒1208. https://doi.org/10.1086/656624

[12]

E.J. Aspinall, G. Hawkins, A. Fraser, et al. Hepatitis B prevention, diagnosis, treatment and care: A review. Occupational Medicine, 2011, 61(8): 531‒540. https://doi.org/10.1093/occmed/kqr136

[13]

L. Koumbi, P. Karayiannis. The epigenetic control of hepatitis B virus modulates the outcome of infection. Frontiers in Microbiology, 2015, 6: 1491. https://doi.org/10.3389/fmicb.2015.01491

[14]

L.C. Meireles, R.T. Marinho, P. Van Damme. Three decades of hepatitis B control with vaccination. World Journal of Hepatology, 2015, 7: 2127‒2132. https://doi.org/10.4254/wjh.v7.i18.2127

[15]

K. Cardell. Studies on hepatitis B vaccination and factors associated with the vaccine response. Linköping: Linköping University Electronic Press, 2009.

[16]

R.K. Gupta, E.H. Relyveld, E.B. Lindblad, et al. Adjuvants — a balance between toxicity and adjuvanticity. Vaccine, 1993, 11(3): 293‒306. http://dx.doi.org/10.1016/0264-410X(93)90190-9

[17]

S.M. Lin, I.S. Sheen, R.N. Chien, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 1999, 29(3): 971‒975. https://doi.org/10.1002/hep.510290312

[18]

L.G. Guidotti, F.V. Chisari. Noncytolytic control of viral infections by the innate and adaptive immune response. Annual Review of Immunology, 2001, 19: 65‒91. https://doi.org/10.1146/annurev.immunol.19.1.65

[19]

E. Oleszycka, E.C. Lavelle. Immunomodulatory properties of the vaccine adjuvant alum. Current Opinion in Immunology, 2014, 28: 1‒5. https://doi.org/10.1016/j.coi.2013.12.007

[20]

M. Kundi. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Review of Vaccines, 2007, 6(2): 133‒140. https://doi.org/10.1586/14760584.6.2.133

[21]

T. Taniyama, T. Watanabe, I. Azuma, et al. Adjuvant activity of mycobacterial fractions. Ⅱ. In vitro adjuvant activity of cell walls of mycobacteria, nocardia and corynebacteria. Japanese Journal of Microbiology, 1974, 18(6): 415‒426. https://doi.org/10.1111/j.1348-0421.1974.tb00829.x

[22]

F. Mavandadnejad, M.H. Yazdi, S.M. Hassanzadeh, et al. Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study. IET Nanobiotechnology, 2018, 12(1): 57‒63. https://doi.org/10.1049/iet-nbt.2017.0006

[23]

Y. Koike, Y.C. Yoo, M. Mitobe, et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine, 1998, 16(20): 1982-1989. http://dx.doi.org/10.1016/S0264-410X(98)00084-X

Nano Biomedicine and Engineering
Pages 308-316
Cite this article:
Yazdi MH, Hassanzade SM, Ajideh R, et al. Green Synthesis of Selenium Nanoparticles in the Presence of Mycobacterium Bovis Cell Lysate: a Novel Fabrication Approachand its Immune-Modulatory Effects. Nano Biomedicine and Engineering, 2022, 14(4): 308-316. https://doi.org/10.5101/nbe.v14i4.p308-316

893

Views

76

Downloads

1

Crossref

1

Scopus

Altmetrics

Received: 22 July 2022
Revised: 20 November 2022
Accepted: 30 December 2022
Published: 31 December 2022
© Mohammad Hossein Yazdi, Seyed Mehdi Hassanzade, Ramak Ajideh, Maryam Mozafar, Faranak Mavandadnejad, Sara Rahimzadeh, Mehdi Mahdavi and Ahmad Reza Shahverdi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return